Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Daunorubicin
Drug: Vincristine
Drug: Prednisone
Drug: PEG-Asparaginase
Drug: Methotrexate
Drug: 6-MP (6-Mercaptopurine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Leucovorin
Drug: Dexamethasone
Other: Blood draw
Device: CT/PET scans

First Posted Date: 2013-08-12

Last Posted Date: 2023-10-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01920737

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Phase 2

Active, not recruiting

Conditions: Stage II Childhood Hodgkin Lymphoma
Stage IV Childhood Hodgkin Lymphoma
Stage III Childhood Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: etoposide
Drug: prednisone
Drug: doxorubicin
Drug: cyclophosphamide
Drug: Dacarbazine(R)
Drug: filgrastim
Other: quality of life assessment
Radiation: radiation therapy

First Posted Date: 2013-08-12

Last Posted Date: 2024-11-21

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 77

Registration Number: NCT01920932

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
Maine Children's Cancer Program (MCCP), Scarborough, Maine, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

and more 3 locations

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

Phase 2

Completed

Conditions: Uveitis

Interventions: Drug: Sarilumab
Drug: Prednisone
Drug: Methotrexate
Drug: Folic/folinic acid
Other: Placebo (for Sarilumab)

First Posted Date: 2013-07-16

Last Posted Date: 2017-06-20

Lead Sponsor: Sanofi

Target Recruit Count: 58

Registration Number: NCT01900431

Locations: 🇺🇸
Investigational Site Number 840007, Cleveland, Ohio, United States
🇹🇷
Investigational Site Number 792004, Izmir, Turkey
🇹🇷
Investigational Site Number 792006, Izmir, Turkey

and more 17 locations

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Phase 2

Withdrawn

Conditions: Acute Interstitial Nephritis

Interventions: Drug: Omalizumab
Drug: Prednisone

First Posted Date: 2013-07-09

Last Posted Date: 2018-12-06

Lead Sponsor: Mayo Clinic

Registration Number: NCT01893658

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Bendamustine

First Posted Date: 2013-06-28

Last Posted Date: 2020-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 159

Registration Number: NCT01889069

Locations: 🇮🇹
Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, Italy
🇮🇹
Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara, Napoli, Campania, Italy
🇮🇹
ASST DI CREMA; U O Oncologia Medica, Crema, Lombardia, Italy

and more 36 locations

Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)

Early Phase 1

Completed

Conditions: Advanced B-cell Lymphoid Malignancies

Interventions: Drug: Prednisone
Drug: Roflumilast

First Posted Date: 2013-06-28

Last Posted Date: 2017-02-27

Lead Sponsor: Anand B. Karnad

Target Recruit Count: 10

Registration Number: NCT01888952

Locations: 🇺🇸
Ctrc @ Uthscsa, San Antonio, Texas, United States

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Prednisone
Drug: VX-509
Drug: Methylprednisolone

First Posted Date: 2013-06-25

Last Posted Date: 2013-08-14

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 28

Registration Number: NCT01886209

Locations: 🇺🇸
Vertex Investigational Site, Lenexa, Kansas, United States

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: Basiliximab
Drug: Methylprednisolone
Drug: Prednisone
Drug: Tacrolimus
Drug: Mycophenolate mofetil

First Posted Date: 2013-06-24

Last Posted Date: 2017-11-06

Lead Sponsor: Emory University

Target Recruit Count: 31

Registration Number: NCT01884571

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2013-05-17

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 349

Registration Number: NCT01856192

Locations: 🇺🇸
Ottumwa Regional Health Center, Ottumwa, Iowa, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States
🇺🇸
MercyOne Waterloo Cancer Center, Waterloo, Iowa, United States

and more 502 locations

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Drug: Alisertib
Drug: Abiraterone acetate
Drug: Prednisone

First Posted Date: 2013-05-07

Last Posted Date: 2017-12-06

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT01848067

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy